Product Information
GS IBUPROFEN 200 MG LIQUID GEL is a generic product labeled by L. Perrigo Company, priced at $0.0762 per EA under NDC 00113029827. Its NADAC has been published 311 times since Oct 21, 2020.
FDA first approved this application on Sep 7, 2016.
Strength
200 mg/1
Manufacturer
L. Perrigo CompanyNDC
00113029827
Classification
Generic
Dosage Form
CAPSULE, LIQUID FILLED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA203599FDA Approved
9/7/2016
On Market Since
2/20/2018
Pharmacological Classes
Price Statistics
The NADAC for GS IBUPROFEN 200 MG LIQUID GEL has been published 311 times since Oct 21, 2020, and over the history we have for it it has declined 8.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0762 per EA |
|---|---|
| All-time high | $0.0979 (Feb 15, 2023) |
| All-time low | $0.0720 (Mar 23, 2022) |
| 52-week high | $0.0816 |
| 52-week low | $0.0762 |
| Median price | $0.0814 |
| Average price | $0.0824 |
| Largest weekly change | -14.7% (Mar 23, 2022) |
| Weeks tracked | 311 |
| Tracking since | Oct 21, 2020 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
L. Perrigo Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GS IBUPROFEN 200 MG LIQUID GEL?
The current National Average Drug Acquisition Cost (NADAC) for GS IBUPROFEN 200 MG LIQUID GEL, manufactured by L. Perrigo Company, is $0.0762 per EA (NDC 00113029827), effective Sep 30, 2026.
How has the price of GS IBUPROFEN 200 MG LIQUID GEL changed over time?
Over the history we have for it, the NADAC for GS IBUPROFEN 200 MG LIQUID GEL has declined 8.7%. It has been tracked across 311 weekly CMS publications since Oct 21, 2020.
What are the highest and lowest recorded NADAC prices for GS IBUPROFEN 200 MG LIQUID GEL?
Since Oct 21, 2020, the NADAC for GS IBUPROFEN 200 MG LIQUID GEL has ranged from a low of $0.0720 (Mar 23, 2022) to a high of $0.0979 (Feb 15, 2023), with a median of $0.0814 per EA.
Are there cheaper alternatives to GS IBUPROFEN 200 MG LIQUID GEL?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as GS IBUPROFEN 200 MG LIQUID GEL in a comparable dosage form, but none are currently priced below it.
Who manufactures GS IBUPROFEN 200 MG LIQUID GEL?
GS IBUPROFEN 200 MG LIQUID GEL (NDC 00113029827) is labeled by L. Perrigo Company, and CMS classifies it as a generic product.